Bioline Rx Ltd ADR (NASDAQ:BLRX) traded with a subtraction of -$0.14 to $1.93 on Thursday, a downside of -6.76 percent. An average of 657,812 shares of common stock have been traded in the last five days. There was a fall of -$0.05 in the past week, and it reached a new high 15 times over the past 12 months. The last 20 days have seen an average of 2,588,138 shares traded, while the 50-day average volume stands at 1,359,087.
BLRX stock has increased by 45.12% in the last month. The company shares reached their 1-month lowest point of $1.26 on 08/29/23. With the stock rallying to its 52-week high on 09/05/23, shares of the company touched a low of $0.55 and a high of $2.53 in 52 weeks. It has reached a new high 26 times so far this year and achieved 227.14% or $1.35 in price. In spite of this, the price is down -23.71% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Bioline Rx Ltd ADR (BLRX) has a trailing price-to-earnings (P/E) ratio of N/A for the broader industry. The stock’s beta is 1.70. Other valuation ratios to consider include the price-to-book (PB) ratio at 5.64.
Financial Health
The quick ratio of Bioline Rx Ltd ADR for the three months ended June 29 was 2.79, and the current ratio was 2.79, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.48 and a total debt to equity ratio of 0.64 for the quarter ending June 29. Its gross profit as reported stood at $2.16 million compared to revenue of $29.16 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$24.95 million in the quarter, while revenues were shrunk -8.42%. The analyst consensus anticipated Bioline Rx Ltd ADR’s latest quarter earnings to come in at -$0.11 per share, but it turned out to be -$0.3, a -172.70% surprise. For the quarter, EBITDA amounted to -$9.72 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Bioline Rx Ltd ADR (BLRX) price momentum. RSI 9-day as of the close on 27 September was 48.96%, suggesting the stock is Neutral, with historical volatility in this time frame at 103.33%.
As of today, BLRX’s price is $2.00 -2.27% or -$0.05 from its 5-day moving average. BLRX is currently trading +39.21% higher than its 20-day SMA and +62.61% higher than its 100-day SMA. However, the stock’s current price level is +19.44% above the SMA50 and +180.43% above the SMA200.
The stochastic %K and %D were 47.34% and 45.10%, respectively, and the average true range (ATR) was 0.21. With the 14-day stochastic at 41.91% and the average true range at 0.21, the RSI (14) stands at 51.64%. The stock has reached -0.07 on the 9-day MACD Oscillator while the 14-day reading was at -0.01.
Analyst Ratings
Maxim Group upgraded Bioline Rx Ltd ADR (NASDAQ: BLRX) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold. The consensus rating for Bioline Rx Ltd ADR (BLRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BLRX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is BLRX’s price target for the next 12 months?
Analysts predict a range of price targets between $7.00 and $21.00, with a median target of $14.00. Taking a look at these predictions, the average price target given by analysts for Bioline Rx Ltd ADR (BLRX) stock is $14.00.
